Clayton, Dubilier & Rice’s Post

Two companies, one vision. Excited for the journey ahead 2025! 🚀 #NewBeginnings" This strategic alliance marks a significant milestone for both companies, promising to drive innovation, expand market reach, and enhance customer experiences. The collaboration between MOHS ANALYTICS and REMED PHARMACEUTICAL INC is built on a shared vision of growth and excellence. By combining their strengths, resources, and expertise, the two companies aim to create a synergy that will propel them to new heights. To know more :https://lnkd.in/gjKBvKyM

🎉 Proudly Sharing My STAD Event 2024 Journey! 🎉 I'm thrilled✨to have completed Phase 1 of the STAD Event 2024, organized by PharmaSchemes! 📚 This incredible program provided 8 insightful sessions, covering crucial areas in the pharmaceutical industry. Here's a glimpse of what I learned: - Negotiation Skills: Mastering the art of effective communication and building strong professional relationships. 🤝 - Time Management & Prioritization: Learning to prioritize tasks and make the most of my time. ⏰ - Strategic Personal Branding: Building a strong professional presence that sets me apart. 🌟 - Sales Career in Pharma: Exploring the impact of pharma sales on healthcare. 🏥 - Enteral & Parenteral Nutrition: Gaining a deeper understanding of nutrition methods. - OTC Medications: Expanding my knowledge of over-the-counter medications and their role in patient care. 💊 This experience has been invaluable, enriching my knowledge and skills, and preparing me for exciting opportunities in pharmaceutical manufacturing. 💪 I'm eager to apply these learnings in my professional journey! #PharmaceuticalIndustry #LearningJourney #ProfessionalDevelopment #PharmaSkills #ClinicalPharmacy #OTCMedications #PharmaSchemes #STADEvent2024 #PersonalBranding #Nutrition

🌟 Navigating Change in Pharma: Sanofi’s Strategic Move 🌟 As Sanofi prepares to sell a 50% controlling stake of its consumer health business, Opella, we witness a significant trend among Big Pharma companies. This echoes previous strategic separations like Johnson & Johnson's spin-off of Kenvue and Novartis’s Sandoz, signaling a broader industry shift towards specialization. The article highlights a crucial point: these moves aren't merely financial; they reflect a strategic refocusing on innovation and streamlined operations. Sanofi’s plan to transition from consumer healthcare to innovative medicines aligns with a growing recognition that focused entities can better respond to market dynamics and consumer needs. 💡 What’s fascinating is how this mirrors historical precedents—Roche's initial move two decades ago set a pattern now adopted by several industry giants. This continual evolution suggests a cycle of adaptation where companies prioritize agility and specialization to thrive in a competitive landscape. As we anticipate the unfolding of Sanofi's plans, it’s essential to consider the implications for stakeholders, employees, and ultimately, patient access to healthcare products. Will these separations lead to greater innovation or create challenges in maintaining brand loyalty and market presence? In an ever-evolving healthcare landscape, keeping an eye on such transitions is vital. How do you think these changes will shape the future of consumer health products? #Sanofi #Kenvue #Novartis #Sandoz #Roche #Pharma #Healthcare #Innovation #BusinessStrategy #ConsumerHealth https://lnkd.in/e2NYEEPx

Joining hands with pharmaceutical companies can lead to transformative care and better healthcare outcomes for everyone. At the core of our mission is a simple yet powerful commitment: to make healthcare better for everyone. And that's exactly what happens when we team up with pharmaceutical companies. Together, we bring the best of both worlds – our nutrition expertise and their cutting-edge medical innovations. Our goal? Improving patient outcomes and making life healthier and happier through a holistic approach to healthcare. By blending our nutrition know-how with their research insights, we're finding new ways to care for patients. From creating special diets to easy-to-understand educational materials, our partnership is all about making healthcare more effective and accessible. One of the best parts? We get to help patients understand their health better. Through clear and helpful resources, we're empowering people on their journey to feeling their best. So, we are always looking to collaborate with more pharmaceutical companies, because when we join forces with pharmaceutical companies, we're not just changing healthcare – we're making it better for everyone. #BetterHealthcareTogether #PartnersInHealth #SimpleSolutions #PatientFirst #PatientEmpowerment #SharedVision #TransformativeCare

Securing the VOWST commercialization right: Nestlé Health Science VOWST is the first and only U.S. Food and Drug Administration (FDA)-approved orally administered microbiota-based therapeutic to prevent recurrence of Clostridioides difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI (rCDI). Seres Therapeutics, Inc. (Nasdaq: MCRB), announced today that it has agreed to a non-binding memorandum of understanding with Nestlé Health Science in which Nestlé Health Science will acquire certain tangible and intangible assets associated with VOWST (fecal microbiota spores, live-brpk) capsules. This transaction, when completed, supersedes any prior agreements between Nestlé and Seres concerning VOWST. Nestlé Health Science has been the lead commercialization party for the product since its launch in June 2023 in the United States. This transaction will allow Nestlé Health Science full control over the further development, commercialization, and manufacturing of VOWST in the US and worldwide. To read our last M&A publication: FMCG CEOs: M&A Q1 2024 In Review - A New Bottom & Four Reinforcing Trends 𝗟𝗶𝗻𝗸 𝘁𝗼 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://lnkd.in/efD5RNWX 𝗧𝗼 𝗴𝗲𝘁 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀 & 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿: https://lnkd.in/ea4gy65y #fmcg #cpg #consumerhealth Haleon Kenvue Sanofi Bayer | Consumer Health Reckitt Procter & Gamble https://lnkd.in/d83Czr9X

Simultaneous offloading of remaining stakes in their consumer health spin-offs by GSK (Haleon - 4.2%) and Johnson & Johnson (Kenvue - 9.5% stake) The move signals the Big Pharma's willingness to cut the ties from its recently spun-off Consumer Health divisions (more of a PR move than strategic, given the size of remaining stake vs the total size of the Pharma business/ market cap, hint: ~1%) The sale will allow Pharma players to sharpen its focus on its key growth drivers vaccines, cancer and infectious diseases. The long-term impact on the Haleon and Kenvue is yet to be seen, but initially the markets have perceived the move negatively for the spin-offs (drops for both Haleon and Kenvue) Exciting times ahead for CHC pure players, one of the most dynamic and interesting #cpg verticals 𝗧𝗼 𝗴𝗲𝘁 𝗮𝗹𝗹 𝗼𝘂𝗿 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀, 𝗳𝗼𝗹𝗹𝗼𝘄 𝘂𝘀/ 𝘀𝘂𝗯𝘀𝗰𝗿𝗶𝗯𝗲 𝘁𝗼 𝗼𝘂𝗿 𝗙𝗠𝗖𝗚 𝗖𝗘𝗢𝘀 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗻𝗲𝘄𝘀𝗹𝗲𝘁𝘁𝗲𝗿: https://lnkd.in/ea4gy65y #fmcg #consumerhealth

Sanofi, a global leader in healthcare based in Paris, is realigning its business strategy by selling a 50% stake in its Consumer Healthcare division, Opella, to private equity firm Clayton, Dubilier & Rice (CD&R). This €16 billion transaction will enable Sanofi to focus on its high-marginality business areas while leveraging CD&R’s expertise to enhance Opella's market position and foster strategic growth. Read more on this article written by Rishav Kumar, Vasara Silininkaite, Thomas Agosti and Alessandro Cera #Sanofi #Opella #healthcare

More and more pharma marketers understand that technological innovation drives success. Read on to hear more about how to navigate the challenges and opportunities new technology can offer.

Get to know your Field Sauce Health Team. Over the coming weeks we will be sharing more information about members of the Field Sauce Health team and the wealth of experience that they bring to your studies. Today the spotlight is on Ewan. Ewan has 20+ years of pharmaceutical Market Research experience and a vast skillset which can be read in his biography below. #FieldSauceHealth #Insights #HealthcareMarketResearch #BHBIA

The Diabetes Mela organized by Dr. Pradeep Gadge and managed by AND Events serves as a platform to bring together experts in the field of diabetes management, healthcare professionals, pharmaceutical companies, and patients. These events typically feature a range of activities such as: 1) Educational Workshops and Seminars 2) Screening and Health Check-ups 3) Interactive Booths and Exhibitions 4) Nutritional Counseling and Cooking Demonstrations 5) Support Groups and Peer Interaction By bringing together healthcare providers, experts, and patients in a collaborative environment, these events play a crucial role in promoting awareness, early detection, and effective management of diabetes—a disease that affects millions of people worldwide. #ANDEvents #ANDIdeas #Diabetes #healthcare #pharmaceutical #patients #EducationalWorkshops #Workshops #Seminars #Exhibitions #Booths #HealthCheckups #Nutritional #pharma #pharmacuticals